tradingkey.logo
搜索

Nautilus Biotechnology Inc

NAUT
添加自选
0.955USD
-0.011-1.14%
收盘 09-21 16:00美东
121.50M总市值
亏损市盈率 TTM

关于 Nautilus Biotechnology Inc 公司

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Nautilus Biotechnology Inc 简介

公司代码NAUT
公司名称Nautilus Biotechnology Inc
上市日期Aug 07, 2020
CEOPatel (Sujal)
员工数量155
证券类型Ordinary Share
年结日Aug 07
公司地址2701 Eastlake Ave East
城市SEATTLE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编98102
电话12063332001
网址https://www.nautilus.bio/
公司代码NAUT
上市日期Aug 07, 2020
CEOPatel (Sujal)

Nautilus Biotechnology Inc公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Ms. Anna Mowry
Ms. Anna Mowry
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
85.50K
+11.70%
Mr. Kentaro (Ken) Suzuki
Mr. Kentaro (Ken) Suzuki
Chief Marketing Officer
Chief Marketing Officer
4.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Dr. Parag Mallick
Dr. Parag Mallick
Chief Scientist, Director
Chief Scientist, Director
20.69M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--
Mr. Farzad (Zod) Nazem
Mr. Farzad (Zod) Nazem
Independent Director
Independent Director
1.89M
--

常见问题

Nautilus Biotechnology Inc的前五大股东是谁?

Nautilus Biotechnology Inc 的前五大股东如下:Dr. Parag Mallick

有多少机构持有Nautilus Biotechnology Inc(NAUT)的股份?

截至2026Q1,共有180家机构持有Nautilus Biotechnology Inc的股份,合计持有的股份价值约为60.30M,占公司总股份的47.66%。与2025Q4相比,机构持股有所增加,增幅为1539418.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有